Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
08 2019
Historique:
received: 15 02 2018
accepted: 26 06 2019
pubmed: 2 8 2019
medline: 27 3 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

Cancer-associated systemic inflammation is strongly linked to poor disease outcome in patients with cancer

Identifiants

pubmed: 31367040
doi: 10.1038/s41586-019-1450-6
pii: 10.1038/s41586-019-1450-6
pmc: PMC6707815
mid: EMS83538
doi:

Substances chimiques

Interleukin-1beta 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
Wnt Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

538-542

Subventions

Organisme : European Research Council
ID : 615300
Pays : International

Références

Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15, e493–e503 (2014).
doi: 10.1016/S1470-2045(14)70263-3
McAllister, S. S. & Weinberg, R. A. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 16, 717–727 (2014).
doi: 10.1038/ncb3015
Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, dju124 (2014).
doi: 10.1093/jnci/dju124
Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16, 431–446 (2016).
doi: 10.1038/nrc.2016.52
Coffelt, S. B. et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).
doi: 10.1038/nature14282
Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G
doi: 10.1073/pnas.1015855107
Bald, T. et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507, 109–113 (2014).
doi: 10.1038/nature13111
Wculek, S. K. & Malanchi, I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528, 413–417 (2015).
doi: 10.1038/nature16140
Park, J. et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016).
doi: 10.1126/scitranslmed.aag1711
Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845 (2016).
doi: 10.1016/j.ccell.2016.04.014
Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 19, 2 (2017).
doi: 10.1186/s13058-016-0794-1
Cooks, T. et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646 (2013).
doi: 10.1016/j.ccr.2013.03.022
Schwitalla, S. et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23, 93–106 (2013).
doi: 10.1016/j.ccr.2012.11.014
Stodden, G. R. et al. Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment. Oncogene 34, 2471–2482 (2015).
doi: 10.1038/onc.2014.193
Wörmann, S. M. et al. Loss of p53 function activates JAK2–STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology 151, 180–193 (2016).
doi: 10.1053/j.gastro.2016.03.010
Bezzi, M. et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat. Med. 24, 165–175 (2018).
doi: 10.1038/nm.4463
Kersten, K. et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. OncoImmunology 6, e1334744 (2017).
doi: 10.1080/2162402X.2017.1334744
Annunziato, S. et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 30, 1470–1480 (2016).
doi: 10.1101/gad.279190.116
Song, X. et al. CD11b
doi: 10.4049/jimmunol.175.12.8200
Singh, V., Holla, S., Ramachandra, S. G. & Balaji, K. N. WNT-inflammasome signaling mediates NOD2-induced development of acute arthritis in mice. J. Immunol. 194, 3351–3360 (2015).
doi: 10.4049/jimmunol.1402498
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
doi: 10.1038/nature14404
Avgustinova, A. et al. Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat. Commun. 7, 10305 (2016).
doi: 10.1038/ncomms10305
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074–3083 (2019).
doi: 10.1158/1078-0432.CCR-18-1942
Kim, N. H. et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal. 4, ra71 (2011).
pubmed: 22045851 pmcid: 3447368
Nusse, R. & Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).
doi: 10.1016/j.cell.2017.05.016
Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399–416 (2018).
doi: 10.1016/j.immuni.2018.03.004
Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589–596 (1998).
doi: 10.1084/jem.188.3.589
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001).
doi: 10.1038/ng747
Derksen, P. W. et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437–449 (2006).
doi: 10.1016/j.ccr.2006.09.013
Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104, 12111–12116 (2007).
doi: 10.1073/pnas.0702969104
Henneman, L. et al. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc. Natl Acad. Sci. USA 112, 8409–8414 (2015).
doi: 10.1073/pnas.1500223112
Huijbers, I. J. et al. Using the GEMM-ESC strategy to study gene function in mouse models. Nat. Protocols 10, 1755–1785 (2015).
doi: 10.1038/nprot.2015.114
Kas, S. M. et al. Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nat. Genet. 49, 1219–1230 (2017).
doi: 10.1038/ng.3905
Annunziato, S. et al. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nat. Commun. 10, 397 (2019).
doi: 10.1038/s41467-019-08301-2
Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).
doi: 10.1073/pnas.1314239110
Doornebal, C. W. et al. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res. 73, 353–363 (2013).
doi: 10.1158/0008-5472.CAN-11-4208
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
doi: 10.1038/nmeth.3047
Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).
doi: 10.1093/nar/gku936
Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240–248 (2009).
doi: 10.1016/j.ymeth.2009.03.001
Lerdrup, M., Johansen, J. V., Agrawal-Singh, S. & Hansen, K. An interactive environment for agile analysis and visualization of ChIP-sequencing data. Nat. Struct. Mol. Biol. 23, 349–357 (2016).
doi: 10.1038/nsmb.3180
Okada, N. et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 28, 438–450 (2014).
doi: 10.1101/gad.233585.113
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
doi: 10.1186/gb-2013-14-4-r36
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
doi: 10.1093/bioinformatics/btp120
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
doi: 10.1093/bioinformatics/btu638
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
doi: 10.1186/gb-2014-15-2-r29
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
doi: 10.1016/j.cels.2015.12.004
Bouaoun, L. et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat. 37, 865–876 (2016).
doi: 10.1002/humu.23035

Auteurs

Max D Wellenstein (MD)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Seth B Coffelt (SB)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.

Danique E M Duits (DEM)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Martine H van Miltenburg (MH)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Maarten Slagter (M)

Division of Molecular Oncology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Iris de Rink (I)

Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Linda Henneman (L)

Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Sjors M Kas (SM)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Stefan Prekovic (S)

Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Cheei-Sing Hau (CS)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Kim Vrijland (K)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Anne Paulien Drenth (AP)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Renske de Korte-Grimmerink (R)

Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Eva Schut (E)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Ingrid van der Heijden (I)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Wilbert Zwart (W)

Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Lodewyk F A Wessels (LFA)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Ton N Schumacher (TN)

Division of Molecular Oncology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jos Jonkers (J)

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.

Karin E de Visser (KE)

Division of Tumour Biology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands. k.d.visser@nki.nl.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH